
Nuvation Bio (NUVB) Stock Forecast & Price Target
Nuvation Bio (NUVB) Analyst Ratings
Bulls say
Nuvation Bio Inc is strategically positioned in the oncology sector with its lead candidate, taletrectinib, demonstrating significant efficacy, as evidenced by an 88.8% confirmed overall response rate and a median progression-free survival of 45.6 months in TKI-naive ROS1+ NSCLC patients. The company's proactive engagement with the FDA regarding safety signals enhances confidence in its clinical trial ethics, while successful approval in China and a revised probability of success for taletrectinib to 60% signals a strong regulatory outlook. Additionally, the anticipated market penetration of 35% due to superior efficacy and updated treatment guidelines presents a compelling growth trajectory for Nuvation Bio's drug portfolio, further supported by its revenue-generating out-licensing agreements.
Bears say
Nuvation Bio Inc faces significant risks that contribute to a negative outlook for its stock, particularly related to its clinical pipeline, including potential negative clinical data and delays in obtaining regulatory approvals for its candidate taletrectinib. The company reported a net loss of $0.15 per share for the fourth quarter of 2024 and is projected to incur a larger net loss of $0.71 per share in 2025, reflecting worsening financial expectations. Compounding these concerns, the company might confront challenges in achieving anticipated commercial uptake of its products due to increasing competition and market dynamics, along with the possibility of long-term dilution risk.
This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.
Nuvation Bio (NUVB) Analyst Forecast & Price Prediction
Start investing in Nuvation Bio (NUVB)
Order type
Buy in
Order amount
Est. shares
0 shares